Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Schering-Plough seeks FDA approval for Intron A combination

April 20, 1998

Mechanism of cytotoxic effect of ImmTher

April 9, 1998

New cell therapy developed at Wistar Institute shows potential as chemotherapy adjuvant

April 9, 1998

AVI BioPharma and ImmunoTherapy announce preliminary results of phase II vaccine study

April 7, 1998

Melacine marketing application granted expedited review by EMEA

April 7, 1998

Campath-1H enters pivotal phase III testing stage

April 7, 1998

Prostate cancer immunotherapeutic evaluated in preclinical and clinical trials

April 6, 1998

Vaxcel acquires rights to cancer antigen

April 6, 1998

Preclinical data indicates efficacy of AltaRex's approach to cancer immunotherapy

April 2, 1998

Merck KGaA initiates worldwide cancer study with BEC2

April 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...